Spectrum’s Neulasta competitor tripped up by manufacturing issues

18th March 2019 Uncategorised 0

Spectrum Pharmaceuticals sold off its portfolio of approved drugs and downsized this year so it could concentrate on its development efforts. Now there is a manufacturing hitch affecting the first of its pipeline products up for approval.

More: Spectrum’s Neulasta competitor tripped up by manufacturing issues
Source: fierce